Bausch Health Companies (BHC) Non-Current Assets (2009 - 2026)
Bausch Health Companies (BHC) reported Non-Current Assets of $18.5 billion for Q1 2026, down 10.48% on a YoY basis from $20.7 billion in Q1 2025, and down 8.36% sequentially from $20.2 billion in Q4 2025.
Bausch Health Companies (BHC) Non-Current Assets (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Non-Current Assets data on file, last reported at $18.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 10.48% year-over-year to $18.5 billion; the trailing twelve-month figure through Mar 2026 stood at $80.1 billion (down 4.59% YoY), and the FY2025 full-year result was $20.2 billion, down 2.6% from the prior year.
- Non-Current Assets slipped to $18.5 billion in Q1 2026, from $20.2 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $23.3 billion in Q1 2022 to a low of $18.5 billion in Q1 2026.
- A 5-year average of $21.2 billion and a median of $21.2 billion in 2023 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets climbed 1.47% in 2023 and decreased 10.48% in 2026, its largest moves.
- Tracing BHC's Non-Current Assets over 5 years: stood at $21.4 billion in 2022, then increased by 1.47% to $21.8 billion in 2023, then dropped by 4.62% to $20.7 billion in 2024, then fell by 2.6% to $20.2 billion in 2025, then fell by 8.36% to $18.5 billion in 2026.
- Business Quant data shows BHC's Non-Current Assets at $18.5 billion in Q1 2026, $20.2 billion in Q4 2025, and $20.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn | 18.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.52 Bn |
| Dec 31, 2025 | 20.21 Bn |
| Sep 30, 2025 | 20.58 Bn |
| Jun 30, 2025 | 20.75 Bn |
| Mar 31, 2025 | 20.69 Bn |
| Dec 31, 2024 | 20.75 Bn |
| Sep 30, 2024 | 21.19 Bn |
| Jun 30, 2024 | 21.28 Bn |
| Mar 31, 2024 | 21.52 Bn |
| Dec 31, 2023 | 21.75 Bn |
| Sep 30, 2023 | 22.02 Bn |
| Jun 30, 2023 | 21.04 Bn |
| Mar 31, 2023 | 21.21 Bn |
| Dec 31, 2022 | 21.44 Bn |
| Sep 30, 2022 | 22.29 Bn |
| Jun 30, 2022 | 22.75 Bn |
| Mar 31, 2022 | 23.25 Bn |
| Dec 31, 2021 | 23.60 Bn |
| Sep 30, 2021 | 23.93 Bn |
| Jun 30, 2021 | 24.59 Bn |